TYPE I INTERFERON INHIBITION IN SYSTEMIC LUPUS ERYTHEMATOSUS

摘要

The disclosure relates to methods and compositions for the treatment of Systemic Lupus Erythematosus (SLE). Specifically, the disclosure relates to methods comprising administering to a subject a type I IFN receptor inhibitor.